A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+

NCT07326215

Status	RECRUITING
Phase	Not Applicable
Sponsor	Vantive Health LLC
Enrollment	99 participants

Key Eligibility Criteria

Inclusion (4)

- Age e 18 years old.
- Invasive mechanical ventilation patients with PaCO2 \> 50 mmHg and pH \< 7.4 under LPV strategy (RR \< 25/min, DP \< 15 cmH2O).
- Expected to be able to tolerate ECCO2R for a minimum of 2h.
- Patients signed a written informed consent; if the right to consent cannot be exercised due to loss of decision-making ability or impairment of consciousness, the legal representative or immediate family member must sign the informed consent document after fully understanding the research content.

Exclusion (10)

- Body weight \< 30 kg.
- Has a contraindication for systemic anticoagulation with heparin according to the Investigator.
- Patient unable to establish extracorporeal circulation access or has a high risk of establishing such access, as judged by the Investigator.
- Allergic to the investigational device/tubing, and/or to the CRRT filters/tubing if combined with CRRT treatment.
- Expected to require extracorporeal membrane oxygenator (ECMO) treatment within 24h after enrollment.

... and 5 more (see full listing online)

Locations (10 total)

China-Japan Friendship Hospital, Beijing, Beijing Municipality, China
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, China
... and 7 more locations